SAN JOSE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Human Pheromone
Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced
that it has filed a Comprehensive Patent Application with the International
Bureau of the World Patent Office for the use of its innovative and previously
undeveloped compound with its origin in sea coral, which has significant
emotional impacts on both men and women, enhancing feelings of positive social
relationships, personal well-being and social attraction.
"We recently announced that we had filed an application with the U.S.
Patent and Trademark Office for this compound, labeled as ER 303, and we have
now followed-up with a patent application with the International Bureau that
will cover major countries outside the United States," a spokesperson
indicated. "This unique technology has worldwide applications, and, as such,
we are also seeking to protect its value in Europe and other primary consumer
markets outside the United States. Seeking this protection is critical in that
we are seeking licensing opportunities with companies having a worldwide
marketing and product presence." The Company reiterated that prior to its
reproduction of this compound, it could only be found in coral reefs off the
coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.
The Company has previously been granted broad-based worldwide patents for
its initial compound, Androstadienone, which has been licensed to leading
marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its
affiliates. An HPS spokesperson indicated that the Company believes that this
additional filing on its new compound should be of interest to the major
consumer products companies around the world.
This news release may contain forward-looking statements that involve
risks and uncertainties that could cause results to differ from predicted
results. Further information on factors that could affect the Company's
results is detailed in the Company's annual report to shareholders on Form 10-
KSB for the year ended December 31, 2007, and Form 10-Q for the nine months
ended September 30, 2008 as filed with the Securities and Exchange Commission.
The Company undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements.
SOURCE Human Pheromone Sciences, Inc.